Synergistic apoptosis-sensitizing effect of PD-L1 inhibitor ARB-272572 encapsulated in TRAIL-expressing extracellular vesicles for renal cell carcinoma therapy
{{output}}
Renal cell carcinoma(RCC) is a therapy-resistant malignancy with rising global incidence, highlighting an urgent need for innovative treatments. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, but ... ...
